Vivek Venkataramani

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

This study shows that IRP1 deficiency in mice leads to metabolic changes that protect against metabolic syndrome by altering mitochondrial function and improving insulin sensitivity.

The paper shows that CISD1 dimerization in PINK1 mutants disrupts iron-sulfur cluster coordination, leading to Parkinson's disease-like phenotypes, and suggests CISD1 as a therapeutic target.

This paper shows MLX and MondoA are essential for male fertility and tumor survival, with MLX regulating metabolism, stress, and germ cell development.